1. Introduction

Type 2 diabetes mellitus (T2DM) is a growing metabolic disease characterized by insulin resistance and hyperglycemia. Current preventative and treatment strategies for T2DM and insulin resistance lack in efficacy resulting in the need for new approaches to prevent and manage/treat the disease better. In recent years, epidemiological studies have suggested that diets rich in fruits and vegetables have beneficial health effects including protection against insulin resistance and T2DM. Curcumin, a polyphenol found in turmeric, and curcuminoids have been reported to have antioxidant, anti-inflammatory, hepatoprotective, nephroprotective, neuroprotective, immunomodulatory and antidiabetic properties. Here we are summarizing the existing in vitro studies examining the antidiabetic effects of curcumin.

2. Effects and Potential Applications

Overall, all available in vitro studies examining the effects of curcumin indicate increased glucose uptake and utilization by skeletal muscle cells and adipocytes, reduced hepatocyte lipid deposition, and inhibition of gluconeogenesis. Pancreatic beta cell function was improved by curcumin treatment. The figure below was created based on the in vitro studies presented in our review ^[1] and summarizes the main effects of curcumin.

Treatment of adipocytes with curcumin (5–100 μM) for up to 72 h resulted in reduced adipocyte differentiation, and lipid accumulation. Macrophage infiltration of adipocytes was reduced with curcumin treatment, as well as pro-inflammatory cytokine production and signaling. In addition, curcumin treatment suppressed adipogenic gene expression, while mitochondrial biogenesis and membrane potential were improved.

Treatment of hepatocytes with curcumin (5–100 μM) for up to 5 days resulted in reduced lipid deposition/lipogenic gene expression. Curcumin treatment significantly reduced inflammatory cytokine and fibrosis gene expression and increased antioxidant activities, resulting in decreased oxidative stress. In addition, gluconeogenesis was reduced, while glucokinase activity and glucose-6-phosphate levels were increased with curcumin treatment.

Figure 1. Cellular effects of curcumin on muscle and fat cellular signaling molecules. The figure was created based on the data of the studies ^{[2][3][4][5][6][7][8][9][10][11][12][13][14]}. AKT: protein kinase B; PIP3: phosphatidylinositol-3,4,5-triphosphate; PIP2: phosphatidylinositol 4,5-bisphosphate; ERK: extracellular signal-regulated kinase; PI3K: phosphoinositide 3-kinase; IRS1: insulin receptor substrate 1; TNF-α: tumor necrosis factor- α; AMPK: AMP-activated protein kinase; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; ACC: acetyl-CoA carboxylase; PGC-1: peroxisome proliferator-activated receptor gamma co-activator 1; FFAs: free fatty acids.

Skeletal muscle cells treated with curcumin (10–50 μM) for up to 24 h had improved glucose uptake and GLUT4 translocation. Curcumin treatment exerted anti-inflammatory effects, it reduced pro-inflammatory mRNA and cytokine levels and increased anti-inflammatory cytokine levels.

Treatment of pancreatic islets with curcumin and curcuminoids (100 pM–57 μM) for up to 24 h resulted in increased insulin secretion and islet cell recovery. HO-1 promoter activity and mRNA and protein levels and antioxidant enzyme activities were significantly increased with curcumin treatment indicating reduced apoptosis and oxidative stress.

The in vitro studies presented in our review ^[1] may have used different curcumin concentrations and different treatment times. A careful examination of the studies revealed that overall, the common curcumin concentrations used were in the micromolar level, with most of the studies using 10–20 μM curcumin.

Discrepancies are shown regarding curcumin’s effects on adipocytes. Studies by Green et al. (2014) ^[15] and Zhang et al. (2016) ^[16] showed that treatment of adipocytes with curcumin resulted in reduced insulin-stimulated glucose uptake and GLUT4 translocation to the plasma membrane ^[15][16]. These data are in contrast to other studies performed on adipocytes, demonstrating antidiabetic effects with curcumin treatment. Therefore, more studies are needed to examine in more detail the effects of curcumin on adipocytes.

Curcumin has the potential to attenuate inflammatory and oxidative stress diseases through increased antioxidant activities. A systematic and meta-analysis review by Wal et al. (2019) ^[17], found that curcumin blocked the oxidation process in mitochondria and reduced ROS and cytokine production and increased the activities of antioxidant enzymes ^[17]. Although increased antioxidant intake, such as curcumin, has been traditionally thought to result in increased health benefits ^[17][18][19], this concept has been recently challenged ^[20][21]. In the review by Halliwell (2013) ^[20], administration of large doses of dietary antioxidants to humans with oxidative diseases had little to no preventative or therapeutic effects. Instead, administration of weak pro-oxidants may have a greater effect on oxidative disease treatment and prevention ^[20]. In 2012, the United States Department of Agriculture (USDA) decided to not utilize the oxygen radical absorbance capacity (ORAC), which indicates the antioxidant power of bioactive compounds, including polyphenols such as curcumin. The decision was due to the belief that in vitro measurements of antioxidant capacity have no relevance to the effects of specific bioactive compounds on human health and that the ORAC values were routinely misused by manufacturing companies to promote their products. Clearly, the mechanisms of action of antioxidants, including curcumin, and the methodology used to quantify the effects require extensive research before human supplementation is recommended.

A search of the literature resulted in many studies focusing on the antidiabetic properties of curcumin and we have prepared two review manuscripts. The first manuscript (Antidiabetic properties of curcumin I: Evidence from in vitro studies) ^[1] focuses on the in vitro evidence (Nutrients, 2020;12(1)). The second manuscript (Antidiabetic properties of curcumin II: Evidence from in vivo studies) ^[22] focuses on the in vivo evidence (Nutrients, 2019;12(1)). Although all the available in vitro and in vivo studies suggest a strong potential of curcumin to be used in the treatment against insulin resistance and T2DM, we acknowledge the need for further clinical studies. Investigations focusing on the effective dose of curcumin in humans as well as the detailed effects on plasma glucose, lipid, insulin and HbA1c levels should be further explored.

This entry is adapted from the peer-reviewed paper 10.3390/nu12010118